Innovent Biologics, Inc. (HKG: 1801)

Innovent Biologics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	8,165	10,052	9,163	8,377	7,764	4,233
Trading Asset Securities	463.49	917.53	3.21	638.21	357.3	462.52
Cash & Short-Term Investments	8,629	10,970	9,166	9,015	8,121	4,695
Cash Growth	1.20%	19.68%	1.67%	11.01%	72.97%	2.12%
Accounts Receivable	1,369	1,006	575.27	968.41	475.38	250.04
Other Receivables	-	-	-	-	91.72	41.18
Receivables	1,369	1,006	575.27	975.91	575.2	304.42
Inventory	690.41	968.09	1,429	1,347	705.66	358.6
Other Current Assets	360.55	484.38	336.52	212.4	64.69	97.25
Total Current Assets	11,049	13,428	11,507	11,551	9,467	5,455
Property, Plant & Equipment	5,421	4,656	3,826	3,090	1,911	1,436
Long-Term Investments	2,301	794.09	630.2	417.26	12.94	1.98
Other Intangible Assets	987.35	27.79	30.05	19.75	-	-
Long-Term Deferred Charges	-	1,242	1,168	752.45	32.63	-
Other Long-Term Assets	537.43	478.64	427.63	412.07	410.15	336.82
Total Assets	20,296	20,627	17,589	16,244	11,835	7,231
Accounts Payable	220.62	372.55	325.62	195.05	120.62	84.28
Accrued Expenses	-	2,156	1,517	1,678	819.95	782.47
Current Portion of Long-Term Debt	934.65	1,195	888	365	255	17
Current Portion of Leases	77.06	25.18	26.39	22.27	16.16	15.55
Current Income Taxes Payable	-	-	3.3	60.59	-	1.75
Current Unearned Revenue	283.55	416.17	434.91	355.51	120.44	41.73
Other Current Liabilities	2,612	312.16	303.71	374.05	153.69	100.78
Total Current Liabilities	4,128	4,477	3,499	3,050	1,486	1,044
Long-Term Debt	2,271	2,327	2,215	2,023	925.18	808
Long-Term Leases	66.26	73.42	98.68	86.39	10.23	24.54
Long-Term Unearned Revenue	990.8	960.05	883.28	753.27	633.96	598.3
Other Long-Term Liabilities	413.94	262.71	162.31	0.34	-	-
Total Liabilities	7,869	8,100	6,859	5,913	3,055	2,474
Common Stock	0.11	0.11	0.11	0.1	0.1	0.09
Additional Paid-In Capital	-	27,324	24,706	22,494	18,541	13,885
Retained Earnings	-	-15,768	-14,740	-12,560	-9,982	-8,984
Comprensive Income & Other	12,426	970.54	763.86	397.02	220.41	-145.65
Total Common Equity	12,426	12,528	10,730	10,330	8,780	4,756
Shareholders' Equity	12,426	12,528	10,730	10,330	8,780	4,756
Total Liabilities & Equity	20,296	20,627	17,589	16,244	11,835	7,231
Total Debt	3,349	3,621	3,229	2,497	1,207	865.09
Net Cash (Debt)	5,280	7,349	5,938	6,518	6,915	3,830
Net Cash Growth	4.06%	23.77%	-8.91%	-5.73%	80.53%	0.64%
Net Cash Per Share	3.29	4.71	3.98	4.48	5.10	3.25
Filing Date Shares Outstanding	1,623	1,622	1,534	1,462	1,403	1,263
Total Common Shares Outstanding	1,623	1,622	1,534	1,462	1,403	1,263
Working Capital	6,921	8,951	8,008	8,501	7,981	4,412
Book Value Per Share	7.66	7.72	6.99	7.07	6.26	3.77
Tangible Book Value	11,439	12,500	10,700	10,311	8,780	4,756
Tangible Book Value Per Share	7.05	7.71	6.97	7.05	6.26	3.77
Buildings	-	402.67	402.46	389.73	389.73	389.73
Machinery	-	2,658	2,523	1,420	1,183	551.48
Construction In Progress	-	2,142	1,139	1,293	287.66	602.49
Leasehold Improvements	-	121.82	107.66	106.85	76.76	53.19

Source: S&P Capital IQ. Standard template. Financial Sources.